Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Management options for persistent functional tumors.

William F Chandler1, Ariel L Barkan, David E Schteingart

  • 1Department of Neurosurgery, University of Michigan Health System, 1500 East Medical Center Drive, Room 2128, Taubman Center, Ann Arbor, MI 48109-0338, USA. wchndler@umich.edu

Neurosurgery Clinics of North America
|April 15, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Use of Recombinant Human Growth Hormone to Protect Against Muscle Weakness in Patients Undergoing Anterior Cruciate Ligament Reconstruction: A Pilot, Randomized Placebo-Controlled Trial.

The American journal of sports medicine·2020
Same author

Localization of basic fibroblast growth factor (bFGFJ) protein and mRNA in human pituitaries: regulation of bFGF mRNA by gonadotropin-releasing hormone.

Endocrine pathology·2020
Same author

Neural cell adhesion molecule (NCAM) in normal and neoplastic human pituitary tissues: Analysis by immunohistochemistry and in situ hybridization.

Endocrine pathology·2020
Same author

Hybridization studies of cultured human pituitary prl and gh producing adenoma cells: Effects of thyrotropin-releasing hormone, somatostatin, and phorbol ester.

Endocrine pathology·2020
Same author

Corticotroph (Basophil) invasion of the pars nervosa in the human pituitary: Localization of proopiomelanocortin peptides, galanin and peptidylglycine α-amidating monooxygenase-like immunoreactivities.

Endocrine pathology·2020
Same author

Growth hormone therapy in adults with growth hormone deficiency: a critical assessment of the literature.

Pituitary·2020
Same journal

Intramedullary Spinal Cord Tumors.

Neurosurgery clinics of North America·2026
Same journal

Spinal Cord Deformities Associated with Intramedullary Spinal Cord Tumors.

Neurosurgery clinics of North America·2026
Same journal

Radiation Therapy for Spinal Cord Tumors.

Neurosurgery clinics of North America·2026
Same journal

Treatment Strategies of Intramedullary Spinal Cord Tumors.

Neurosurgery clinics of North America·2026
Same journal

Vascular Lesions of the Spinal Cord: Arteriovenous and Cavernous Malformations.

Neurosurgery clinics of North America·2026
Same journal

Hemangioblastomas of the Spinal Cord.

Neurosurgery clinics of North America·2026
See all related articles

This article details managing patients with persistent functional pituitary tumors after surgery. It outlines medical, surgical, and radiation treatments for growth hormone, adrenocorticotrophic hormone, prolactin, and thyroid stimulating hormone-producing tumors.

Area of Science:

  • Endocrinology
  • Neurosurgery
  • Oncology

Background:

  • Functional pituitary tumors can persist after initial surgical treatment.
  • Persistent tumor function requires specific management strategies.
  • Tumor types include those producing growth hormone, adrenocorticotrophic hormone, prolactin, and thyroid stimulating hormone.

Purpose of the Study:

  • To define "persistent function" for various functional pituitary tumors.
  • To outline current management options for patients with persistent functional pituitary tumors.
  • To provide a comprehensive overview of medical, surgical, and radiation therapies.

Main Methods:

  • Literature review of current management strategies.
  • Analysis of treatment outcomes for different tumor types.

Related Experiment Videos

  • Definition of persistent function based on hormonal levels and imaging.

    • Main Results:

    • Detailed descriptions of persistent function criteria for each tumor type.
    • Comprehensive review of medical therapies (e.g., dopamine agonists, somatostatin analogs).
    • Surgical and radiation options are presented for each specific functional tumor type.

    Conclusions:

    • Effective management of persistent functional pituitary tumors requires a multidisciplinary approach.
    • Treatment selection depends on tumor type, patient factors, and treatment goals.
    • Further research is needed to optimize long-term outcomes for these patients.